Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Depreciation & Amortization (CF) of $454000.0 for Q1 2026, up 156.5% year-over-year from $177000.0 in Q1 2025, and up 2.71% quarter-over-quarter from $442000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $454000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 156.5% year-over-year to $454000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 159.15% YoY), while the FY2025 annual figure was $1.3 million, up 125.3% from the prior year.
- Depreciation & Amortization (CF) climbed to $454000.0 in Q1 2026 per VVOS's latest filing, from $442000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $454000.0 in Q1 2026 and bottomed at $41000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $213764.7 across 5 years, with a median of $169000.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 76.84% — and 2023, when it surged 326.83%.
- Vivos Therapeutics' Depreciation & Amortization (CF) stood at $169000.0 in 2022, then decreased by 11.83% to $149000.0 in 2023, then declined by 3.36% to $144000.0 in 2024, then soared by 206.94% to $442000.0 in 2025, then rose by 2.71% to $454000.0 in 2026.
- Business Quant data shows VVOS's Depreciation & Amortization (CF) at $454000.0 in Q1 2026, $442000.0 in Q4 2025, and $384000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | - |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | 716.00 Mn |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | 355.00 Mn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 42.70 Mn |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | 68.20 Mn |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 750.89 Mn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | 123.80 Mn |
| 10 | Vivos Therapeutics | 4.96 Mn | 3.16 Mn | 2.95 Mn | 510,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 454,000.00 |
| Mar 31, 2026 | 454,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | 149,000.00 |
| Dec 31, 2023 | 149,000.00 |